Skip to content

Beisol Pharma Meerle

Active
Private limited company (pre-2019)founded 2014active for 12 yearsStaatsbaan(LUB) 187, 3210 Lubbeek, BelgiumKBO/BCE: BE 0544.650.644
Summary

Beisol Pharma Meerle has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show negative equity (-€61,896) and a net result of €10,337. Equity has been shrinking by about 33% per year since 2019. Its solvency ranks better than 5% of 56 sector peers (NACE 77, financial year 2026). The computed 12-month bankruptcy probability is 1.1% (low).

Overview

Official details

Source: KBO
Status
Active since 22-01-2014 Normal situation
Registered office
11 active companies are registered at this address Source: KBO register, as of 4 November 2026.
Activity
Rental and leasing activities NACE 77400
Establishment unit
2.226.735.067 3210 Lubbeek, since 22-01-2014
Financial year end
31 March
Peppol
Reachable since 19-12-2025

Financial position

54 Fair Checked score 2026
Bankruptcy probabilitywithin 12 months
1.1%
Annual accounts to 31-03-2026
Turnover
€20,480
=
Profit
€10,337
▼ 16.5%
Equity
-€61,896
▲ 14.3%
Total assets
€128,773
▼ 6.3%
  • Negative equity on 31-03-2026
Score breakdownraises riskCapped at 59: negative equityNegative equity -€61,896Liquidity: current ratio 0.68, cash €31, halvedlowers riskSize: turnover €20,480, total assets €128,773Founded in 2014Show the evidence

Checked score

Score 2026
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 26% of micro companies in rental and leasing (NACE 77)
Negative equity caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick: 2025
Weak
Solvency 0=
equity -48.1% of total assets
Liquidity 0=
short-term debt 148.1% · cash 0.0%
Profitability 58-2
return on assets 8.0%
Bankruptcy probability within 12 months
1.1% Low
0%0.5%1.5%4%10%≥ 25%

About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.5% (3,169 companies, NACE 77, micro)
Last 24 months 12-2024: 2.4%highest value 01-2025: 2.3%▼ -0.1 percentage points vs 12-2024 02-2025: 2.2%▼ -0.1 percentage points vs 01-2025 03-2025: 2.2%● unchanged vs 02-2025 04-2025: 2.3%▲ +0.1 percentage points vs 03-2025 05-2025: 2.3%● unchanged vs 04-2025 06-2025: 2.3%● unchanged vs 05-2025 07-2025: 2.4%▲ +0.1 percentage points vs 06-2025 08-2025: 2.3%▼ -0.1 percentage points vs 07-2025 09-2025: 2.1%▼ -0.2 percentage points vs 08-2025 10-2025: 2.2%▲ +0.1 percentage points vs 09-2025 11-2025: 1.0%▼ -1.2 percentage points vs 10-2025 12-2025: 1.0%● unchanged vs 11-2025 01-2026: 1.0%● unchanged vs 12-2025 02-2026: 1.0%● unchanged vs 01-2026 03-2026: 1.0%● unchanged vs 02-2026 04-2026: 1.0%● unchanged vs 03-2026 05-2026: 1.0%● unchanged vs 04-2026 06-2026: 1.0%● unchanged vs 05-2026 07-2026: 1.1%▲ +0.1 percentage points vs 06-2026 08-2026: 1.1%● unchanged vs 07-2026 09-2026: 1.0%▼ -0.1 percentage points vs 08-2026lowest value 10-2026: 1.1%▲ +0.1 percentage points vs 09-2026 11-2026: 1.1%● unchanged vs 10-2026
No credit on open account
Liquidity is insufficient, with a current ratio of 0.68 (0.66 in 2025), below 1. Short-term debt is 148.1% and cash 0% of total assets. Equity is negative.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 77, micro). It does better than 7% of them on solvency, 1% on liquidity, 37% on profitability and 57% on growth.

The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · Negative equity -€61,896
NBB · annual accounts
lowers risk · Size: turnover €20,480, total assets €128,773
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Liquidity: current ratio 0.68, cash €31, halved
NBB · annual accounts
lowers risk · Founded in 2014
Companies that have existed this long fail less often. How much that weighs depends on the rest of the company's profile.
KBO
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 5% of 56 sector peers (2026).
NBB · sector comparison
Position among 56 sector peers
Solvency
better than 5%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 05-10-2026, 26 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
26 days early
2025
10 days early
2024
16 days early
2023
8 days early
2022
14 days early
2021
31 days early
2020
15 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 13 days before the deadline. In the sector (NACE 77), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 17 October (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
04-11-2026 today31-03-2027 year end31-10-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Risk: Negative equitydebts exceed assets in financial year 2026 -€61,896 View
  • Caution: Lower solvency than 95% of companies in rental and leasingsector median 31.2% · 56 companies -48.1% View
  • Positive: Filed on time since financial year 2021accounts within the deadline every year 6 years View

Recent changes

  1. · Gazette deed Incorporation
All 13 events

Comparable companies

These companies have the same main activity as Beisol Pharma Meerle: rental and leasing activities (NACE 77400). They are comparable in size and age: total assets between €95,400 and €273,000, founded between 2012 and 2014.

CompanyTotal assetsGross margin
Beisol Pharma Meerle Lubbeek€128,773€10,804
Beisol Pharma Poederlee Lubbeek€99,614€8,040
Beisol Pharma Kortenberg Lubbeek€236,490€12,693
Beisol Pharma Merkplas Lubbeek€255,874€21,933
Beisol Pharma Neerijse Lubbeek€95,422€3,387
Beisol Pharma Tienen Lubbeek€121,648€3,096
VANDENBEMPT PATENT Leuven€272,504€14,075
Full comparison

Key facts about Beisol Pharma Meerle

What is the company number of Beisol Pharma Meerle?
The company number of Beisol Pharma Meerle is 0544.650.644. The VAT number is the same number with BE in front: BE 0544.650.644.
Where is Beisol Pharma Meerle based?
The registered office is at Staatsbaan(LUB) 187, 3210 Lubbeek.Company details
What does Beisol Pharma Meerle do?
According to the KBO register, the main activity is rental and leasing activities (NACE 77400).
What is the legal form of Beisol Pharma Meerle?
The legal form of Beisol Pharma Meerle is Private limited company (pre-2019) (BVBA).
When was Beisol Pharma Meerle founded?
Beisol Pharma Meerle was founded on 22-01-2014.
Is Beisol Pharma Meerle still active?
Yes, Beisol Pharma Meerle is an active enterprise in the KBO register.
What is the turnover of Beisol Pharma Meerle?
The turnover of Beisol Pharma Meerle was €20,480 in financial year 2026, according to the filed annual accounts.Financials
Is Beisol Pharma Meerle profitable?
In financial year 2026, Beisol Pharma Meerle made a profit of €10,337.
Where can I find the annual accounts of Beisol Pharma Meerle?
Beisol Pharma Meerle filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of Beisol Pharma Meerle due?
Beisol Pharma Meerle must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.